Detail akcie CHUGAI PHARM online

Business Summary: Chugai Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Chugai Pharmaceutical Co Ltd revenues increased 5% to Y911.64B. Net income applicable to common stockholders increased 3% to Y305.6B. Revenues reflect Switzerland segment increase of 6% to Y541.86B, Japan segment increase of 4% to Y345.01B, Other foreign segment increase of 3% to Y24.77B. Dividend per share increased from Y41.00 to Y50.00.